Skip to content

Change in AP at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$3.92B-84.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.9M-39.4%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$6.8M+1,811%
TG Therapeutics logo
TG TherapeuticsTGTX
$34.02M-47.8%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s change in AP?
Immunovant, Inc. (IMVT) reported change in AP of -$1.35M in Q1 2026.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.